Fundraising Fox
/Companies
Sign in

Gliknik

Baltimore, US · Delaware corporation · 5 known investors

Find your way into Gliknik

Sign up to see every warm intro you have to Gliknik

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Gliknik team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.

Biotech

Founders & leadership

DSDavid S. Block
David S. BlockFounder
EC
Elizabeth C. BlockExecutive
RS
Raymond ShinaziNamed on SEC filing
JK
Joseph KleinNamed on SEC filing
ML
Mark LernerNamed on SEC filing

Board

CP
Charles PolskyBoard director
DB
David BroserBoard director
RS
Raymond SchinaziBoard director
KRKyle Rusconi
Kyle RusconiBoard directorGeneral Partner at First In Ventures
RL
Richard LevyBoard director
PA
Paul A. FriedmanBoard director

Investors · 5

First In Ventureslisted by First In VenturesMiddletown · $50K – $200Kvia Kyle Rusconi · board

How we know: First In Ventures's portfolio page · board seat on SEC Form D · the VCSheet dataset · Not right? Tell us

Also in the syndicate · 3

Baxter VenturesleadLifeTech Developments FundPfizer

Funding

SEC filings, press & company announcements

$33.8M disclosed across 4 of 6 rounds · 2012–2025

  • Undisclosed amountSeries BOct 2012

    Baxter Ventures (lead), LifeTech Developments Fund

    Source ↗
▶$15MraisedSep 2026 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David S. BlockExecutive Officer, Director
  • Charles PolskyDirector
  • Kyle RusconiDirector
  • Raymond SchinaziDirector
  • Richard S. LevyDirector
  • Paul FreidmanDirector
  • Elizabeth BlockExecutive Officer
  • David BroserDirector
Offering amount
$15M
Amount sold
$15M
Proceeds to insiders
$670K
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.3MraisedJan 2025 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles PolskyDirector
  • David BroserDirector
  • Richard LevyDirector
  • Paul A. FriedmanDirector
  • David S. BlockExecutive Officer, Director
  • Raymond SchinaziDirector
  • Elizabeth C. BlockExecutive Officer
  • Kyle RusconiDirector
Offering amount
$6M
Amount sold
$5.3M
Proceeds to insiders
$500K
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$9.2MraisedMar 2024 · 23 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott Eric StromeDirector
  • Richard S. LevyDirector
  • David S. BlockExecutive Officer, Director
  • Paul A. FriedmanDirector
  • David BroserDirector
  • Kyle J. RusconiDirector
  • Charles V. PolskyDirector
  • Raymond F. SchinaziDirector
  • Elizabeth C. BlockExecutive Officer
  • Mark D. LernerDirector
Offering amount
$16.2M
Amount sold
$9.2M
Proceeds to insiders
$500K
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedJun 2021 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Raymond ShinaziDirector
  • Joseph KleinDirector
  • Elizabeth BlockExecutive Officer
  • David S. BlockExecutive Officer, Director
  • Richard LevyDirector
  • Mark LernerDirector
  • Paul A. FriedmanDirector
Offering amount
$12M
Amount sold
$4.3M
Minimum investment
$25K
First sale
May 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

OupOxford University Press (OUP) provides dictionary data, language datasets, and lexical content in over 60 languages to power digital literacy tools, educational software, gaming platforms, and media experiences. The company works across reading apps, word games, quiz shows, and broadcast media to expand access to language learning and comprehension.

Companies working in the same space as Gliknik.

In the news

Gliknik Raises $4.9 Million In Series B Financing Led By Baxter Venturesprnewswire.com · Oct 2012National Cancer Institute Awards Gliknik Up to $1.5 Million in SBIR Fundingprnewswire.com · Oct 2011

Frequently asked questions

What does Gliknik do?
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
Who founded Gliknik?
Gliknik was founded by David S. Block.
Who are Gliknik's investors?
Gliknik's investors include Brace Pharma, First In Ventures.
How much funding has Gliknik raised?
Gliknik has disclosed $33.8M raised across 4 of its 6 known rounds.
Where is Gliknik headquartered?
Gliknik is headquartered in Baltimore, US.